文献速递前列腺癌

前列腺健康指数密度提高临床显著前列腺癌的检出

Prostate Health Index density improves detection of clinically significant prostate cancer.
PubMed 文献 · BJU Int · 2017-02-06

该前瞻性单中心研究纳入2015年在本院因PSA升高(>2 ng/mL)且直肠指检阴性而接受前列腺健康指数(PHI)检测和前列腺活检的118例男性,评估PHI密度对临床显著前列腺癌的检出价值。结果显示PHI密度对临床显著前列腺癌的鉴别能力最高(AUC 0.84),以0.43为阈值可避免38%的不必要活检,仅漏检2%的临床显著癌。

要点

  • PHI密度对临床显著前列腺癌的鉴别能力(AUC 0.84)高于PSA、PSA密度、%free PSA、%free PSA与前列腺体积乘积及PHI。
  • 以0.43为阈值,PHI密度检出临床显著前列腺癌的敏感性为97.9%,对Gleason评分≥7疾病敏感性为100%。
  • PHI密度<0.43组临床显著前列腺癌检出率为3.6%,0.43-1.21组为36.7%,>1.21组为80.0%。

核心结论

  • 基于本前瞻性单中心经验,PHI密度可用于避免38%的不必要活检,同时仅漏检2%的临床显著前列腺癌。

研究设计与样本

  • 前瞻性单中心研究,纳入2015年在本院因PSA>2 ng/mL且直肠指检阴性而接受PHI检测和前列腺活检的118例男性。
  • 血清标志物按标准临床路径前瞻性检测,PHI计算公式为([-2]proPSA/free PSA)×(PSA)½,密度计算使用经直肠超声测定的前列腺体积。
  • 采用逻辑回归评估血清标志物预测临床显著前列腺癌的能力,临床显著前列腺癌定义为任何Gleason评分≥7的癌症或Gleason评分6的癌症在>2针或任一阳性针>50%中。

主要发现

  • 118例接受活检的男性中,47例(39.8%)活检发现临床显著前列腺癌。
  • PHI密度中位数(四分位距[IQR])为0.70(0.43-1.21);活检阴性或临床不显著前列腺癌男性为0.53(0.36-0.75),临床显著前列腺癌男性为1.21(0.74-1.88)(P < 0.001)。
  • PHI密度第一四分位(<0.43)组临床显著前列腺癌检出率为3.6%,PHI密度IQR(0.43-1.21)组为36.7%,PHI密度>1.21组为80.0%(P < 0.001)。
  • 以0.43为阈值,PHI密度检出临床显著前列腺癌的敏感性为97.9%,特异性为38.0%,对Gleason评分≥7疾病敏感性为100%。
  • 临床显著前列腺癌的鉴别能力:PSA的AUC为0.52,PSA密度的AUC为0.70,%free PSA的AUC为0.75,%free PSA与前列腺体积乘积的AUC为0.79,PHI的AUC为0.76,PHI密度的AUC最高为0.84。

关键数值与推荐

  • PHI密度阈值0.43:检出临床显著前列腺癌敏感性97.9%,特异性38.0%,对Gleason评分≥7疾病敏感性100%。
  • PHI密度<0.43组临床显著前列腺癌检出率3.6%,0.43-1.21组36.7%,>1.21组80.0%(P < 0.001)。

临床怎么用

  • 作者认为,基于本前瞻性单中心经验,PHI密度可用于避免38%的不必要活检,同时仅漏检2%的临床显著前列腺癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the utility of Prostate Health Index (PHI) density for the detection of clinically significant prostate cancer (PCa) in a contemporary cohort of men presenting for diagnostic evaluation of PCa. PATIENTS AND METHODS: The study cohort included patients with elevated prostate-specific antigen (PSA; >2 ng/mL) and negative digital rectal examination who underwent PHI testing and prostate biopsy at our institution in 2015. Serum markers were prospectively measured per standard clinical pathway. PHI was calculated as ([{-2}proPSA/free PSA] × [PSA]½ ), and density calculations were performed using prostate volume as determined by transrectal ultrasonography. Logistic regression was used to assess the ability of serum markers to predict clinically significant PCa, defined as any Gleason score ≥7 cancer or Gleason score 6 cancer in >2 cores or >50% of any positive core. RESULTS: Of 118 men with PHI testing who underwent biopsy, 47 (39.8%) were found to have clinically significant PCa on biopsy. The median (interquartile range [IQR]) PHI density was 0.70 (0.43-1.21), and was 0.53 (0.36-0.75) in men with negative biopsy or clinically insignificant PCa and 1.21 (0.74-1.88) in men with clinically significant PCa (P < 0.001). Clinically significant PCa was detected in 3.6% of men in the first quartile of PHI density (<0.43), 36.7% of men in the IQR of PHI density (0.43-1.21), and 80.0% of men with PHI density >1.21 (P < 0.001). Using a threshold of 0.43, PHI density was 97.9% sensitive and 38.0% specific for clinically significant PCa, and 100% sensitive for Gleason score ≥7 disease. Compared with PSA (area under the curve [AUC] 0.52), PSA density (AUC 0.70), %free PSA (AUC 0.75), the product of %free PSA and prostate volume (AUC 0.79), and PHI (AUC 0.76), PHI density had the highest discriminative ability for clinically significant PCa (AUC 0.84). CONCLUSIONS: Based on the present prospective single-centre experience, PHI density could be used to avoid 38% of unnecessary biopsies, while failing to detect only 2% of clinically significant cancers.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Druskin SC, Andreas D, et al. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int. 2017. PMID: 28058757. doi:10.1111/bju.13762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。